It's hard to find any info on it since it's preclinical. the pre-clinical development of BCX5191, a novel and proprietary nucleoside analog targeting RNA polymerase for hepatitis C with a goal for IND filing in 2012 http://sg.news.yahoo.com/bc-nc-biocryst-pharm-104532860.html